Inspired by rare genetic disease, researchers develop a compound that can protect kidney cells from death and restore kidney function in multiple animal models of progressive kidney disease.
Progressive kidney diseases, whether caused by obesity, hypertension, diabetes, or rare genetic mutations, often have the same outcome: The cells responsible for filtering the blood are destroyed. Reporting today in Science, a team led by researchers from the Broad Institute of MIT and Harvard, Brigham and Women’s Hospital, and Harvard Medical School describes a new approach to prevent death in these essential kidney cells.
Studying multiple animal models of kidney disease, the team discovered a compound that can impede loss of the filtration cells and restore kidney function. The work, inspired by an investigation into a genetic form of the condition, has the potential to affect therapeutic research for millions of people suffering from progressive kidney diseases.
“We’re ultimately trying to create a drug that can protect these critical filtration cells in the kidney,” said senior author Anna Greka, an institute member at Broad, associate physician at Brigham and Women’s Hospital, and assistant professor at Harvard Medical School. “We attacked the problem from the biology of the genetic disease, and we think we’ve actually found what might be a shared pathway for kidney failure — and a potential way to treat it.”
Treatment options for kidney disease are few and far between, and the last 40 years have seen virtually no progress in new drug development. Patients who receive a transplant often experience complications, and the majority of patients eventually die on dialysis. Of note, the cost of dialysis care in the United States is 50 billion dollars per year, which dwarfs the entire NIH budget.
In order to address this, Greka and her colleagues began their investigation with a rare genetic type of kidney disease, and, using a rat model, set out to understand the genes, proteins, and pathways involved in the organ’s deterioration. The kidney damage is characterized by loss of the filtration cells, or “podocytes,” which normally keep essential proteins in the blood and filter out toxins. When these cells are destroyed, proteins from the blood start spilling out into the urine, a symptom called proteinuria.
Previous work indicated that the genetic mutations in this disease activate a protein called Rac1. Greka’s team revealed that Rac1 then activates a protein called TRPC5 in a damaging feedback loop. In diseased kidneys, TRPC5 causes an influx of calcium ions into the podocyte, eventually destroying it. The researchers designed and tested a variety of compounds to find one that could block this process, and identified a small molecule they called AC1903 (named after Anna Greka and co-author Corey Hopkins of the University of Nebraska Medical Center College of Pharmacy) that looked promising.
In a genetic rat model of progressive kidney disease, AC1903 protected the kidney’s filtration cells. Even when animals began treatment at advanced stages of the disease, AC1903 was able to prevent further podocyte loss and suppress proteinuria, indicating restored kidney function.
“We could literally count the podocytes and see that the cells were preserved with this treatment,” said Greka. “We learned from the genetics, identified the pathway, and then targeted that cellular biology.”
But the team didn’t stop there. The researchers predicted that the TRPC5 mechanism might play a similar role in other types of progressive kidney disease — even if, in those cases, the damaging feedback loop was kickstarted from chronic disorders such as high blood pressure, rather than a specific genetic mutation.
The team tested AC1903 in a rat model of kidney disease caused by hypertension and saw the same results: The treatment preserved kidney podocytes and prevented the organs from failing, even in advanced disease.
The results suggest that TRPC5 channels are activated by a variety of kidney stressors, and that TRPC5 inhibitors may be able to broadly prevent a breakdown of the kidney filter. These compounds may form the basis for much-needed, mechanistically based therapies for progressive kidney diseases.
“Even after we see this rip-roaring, terrible disease that just wreaks havoc on the kidneys, we were able to prevent further damage in these rat models,” said Greka. “Of course, we now need to test TRPC5 inhibitors in clinical studies in patients, but the results are very exciting. The field has waited a very long time — decades, really — for a genetically-inspired, mechanism-based therapy. I’m delighted that our team has contributed to this finally approaching a reality.”
The Latest on: Progressive kidney disease
- LncRNA SNHG16 induces proliferation and fibrogenesis via modulating miR-141-3p and CCND1 in diabetic nephropathyon June 5, 2020 at 8:28 am
LncRNAs are reported to participate in the progression of various diseases including diabetic nephropathy. Currently, we reported that SNHG16 was obviously upregulated in db/db mice and high ...
- Protecting the injured kidneyon June 5, 2020 at 6:17 am
The proximal tubule—part of the kidney's nephron—is a target of acute kidney injury (AKI), and its response to injury determines whether the kidney undergoes repair or progresses to chronic kidney ...
- Dimerix’s lead candidate to enter global REMAP-CAP trial to treat COVID-19 ARDSon June 4, 2020 at 3:36 pm
PERTH, Australia – Melbourne, Australia-based Dimerix Ltd. saw its shares gain 66% on the news that its lead candidate, DMX-200, has been chosen to enter the global REMAP-CAP platform trial as a ...
- Nox4 protein can be used as a marker to predict untreatable kidney canceron June 4, 2020 at 10:16 am
A team of researchers from The University of Texas Health Science Center at San Antonio confirmed the role of a certain protein in the development of high-grade kidney cancer.
- Insights on Metabolic Acidosis (MA) an Epidemiology Forecast to 2030 - ResearchAndMarkets.comon June 4, 2020 at 8:59 am
This report delivers an in-depth understanding of the disease, along with historical and forecasted Metabolic Acidosis epidemiology in 7 major markets (7MM) the United States, Germany, France, Italy, ...
- Biotech Stocks: Buy This, Not Thaton June 4, 2020 at 7:34 am
A crucial aspect of success in investing in biotech stocks is that of timing. Buying a stock too early can mean enduring infinite dilution and clinical trial failures before a company can finally ...
- Study shows Nox4 protein may predict untreatable kidney canceron June 4, 2020 at 6:30 am
A team of researchers from The University of Texas Health Science Center at San Antonio confirmed the role of a certain protein in the development of high-grade kidney cancer. The researchers also ...
- UT Health San Antonio study shows Nox4 protein may predict untreatable kidney canceron June 4, 2020 at 6:10 am
University of Texas Health Science Center at San Antonio researchers confirmed the role of a certain protein, Nox4, in the development of high-grade kidney cancer. The researchers also showed that a ...
- Aveo’s Tivozanib Gets FDA Nod For New Drug Application To Treat Kidney Canceron June 2, 2020 at 1:10 am
Aveo Oncology (AVEO) announced that the U.S. Food and Drug Administration approved the New Drug Application (NDA) for its tivozanib used for the treatment of kidney cancer. Tivozanib is the company ..
- Global Polycystic kidney Disease Marketon May 28, 2020 at 8:11 am
This Global Polycystic kidney Disease Market research report helps to save time as well as add credibility to the work that is done for the growth of business The report assists all sizes of ...
via Google News and Bing News